<DOC>
	<DOCNO>NCT00096369</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent development recurrence cancer . The use tamoxifen may effective prevent breast cancer . PURPOSE : This randomized phase II trial study tamoxifen see well work compare placebo prevent breast cancer woman increase risk disease .</brief_summary>
	<brief_title>Tamoxifen Preventing Breast Cancer Women Increased Risk Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare molecular marker proliferation apoptosis breast epithelial tissue woman increase risk breast cancer treat tamoxifen v placebo . - Compare modulation marker genomic instability breast epithelial tissue patient treat drug . - Compare serum level IGF-1 , IGF-2 , IGFBP-3 patient baseline treatment drug . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord estimate 5-year breast cancer risk ( 1.67-5 % v ≥ 5 % ) , presence atypical ductal hyperplasia ( yes v ) , menopausal status ( premenopausal v postmenopausal ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral tamoxifen daily . - Arm I : Patients receive oral placebo daily . Treatment arm continue 3 month absence invasive breast cancer unacceptable toxicity . Patients undergo core needle biopsy fine needle aspiration biopsy baseline completion study treatment ( premenopausal patient ) ; exactly 84 day first biopsy ( postmenopausal patient ) ; first second day menstrual cycle 84 day ( third menstrual cycle ) first dose study medication ( patient irregular menses ) . Patients follow 30 day . PROJECTED ACCRUAL : A total 130 patient ( 65 per arm ) accrue study within 30 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : At increase risk breast cancer , define 1 follow criterion : Histologically confirm lobular carcinoma situ ( LCIS ) treat local excision Composite increase breast cancer risk ≥ 1.67 % 5 year , base follow criterion : Age Number firstdegree female relative breast cancer One prior breast biopsy Fineneedle aspiration cytology noncystic lesion lieu open biopsy consider biopsy Prior diagnosis atypical hyperplasia breast Age first live birth Nulliparity Race Age onset menarche No prior suspect invasive breast cancer ductal carcinoma situ No clinical evidence malignancy physical examination , include breast examination within past 3 month No evidence suspicious malignant disease uncharacterized lesion bilateral mammogram within past 6 month Normal gynecologic examination , include bimanual pelvic examination , indicate , pap smear within past 12 month Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 35 Sex Female Menopausal status Premenopausal ovulating* , define regular menses past 6 month OR irregular menses follicular phase ( i.e. , day 3 ) folliclestimulating hormone level &lt; 20 mIU/mL OR Postmenopausal NOTE : * Ovulation determine day 21 progesterone level &gt; 3 ng/mL Performance status ECOG 02 Life expectancy Not specify Hematopoietic Complete blood count normal No active bleeding disorder ( e.g. , qualitative quantitative platelet abnormality , hemophilia , von Willebrand 's disease ) Hepatic Liver function test normal Renal Not specify Cardiovascular No prior deepvein thrombosis except single occurrence relate low extremity trauma No prior cerebral vascular accident No prior transient ischemic attack Pulmonary No prior pulmonary embolus except single occurrence relate low extremity trauma Other No saline silicone breast implant No known allergy tamoxifen No macular degeneration No malignancy within past 5 year except basal cell squamous cell skin cancer carcinoma situ cervix No nonmalignant disease would preclude administration tamoxifen No psychiatric condition , include history clinical depression addictive disorder , would preclude give informed consent study compliance Not pregnant nursing Negative pregnancy test Fertile patient must use effective nonhormonal contraception 3 month study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior systemic adjuvant chemotherapy LCIS Endocrine therapy No prior tamoxifen , raloxifene , selective estrogenreceptor modulators At least 3 month since prior concurrent use follow drug : Estrogen progesterone replacement therapy Oral contraceptives Androgens Luteinizing hormonereleasing hormone analog Prolactin inhibitor Antiandrogens Steroids No concurrent steroid asthma Radiotherapy No prior radiotherapy LCIS Surgery No prior bilateral prophylactic mastectomy No prior mastectomy LCIS Other Concurrent nonhormonal medication allow No concurrent warfarin cholestyramine No prior concurrent participation cancer prevention study Patients treat placebo protocol NSABPP1 eligible</criteria>
	<gender>Female</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
	<keyword>breast cancer</keyword>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>breast cancer situ</keyword>
</DOC>